GB201702221D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB201702221D0
GB201702221D0 GBGB1702221.1A GB201702221A GB201702221D0 GB 201702221 D0 GB201702221 D0 GB 201702221D0 GB 201702221 A GB201702221 A GB 201702221A GB 201702221 D0 GB201702221 D0 GB 201702221D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1702221.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Sussex
Original Assignee
University of Sussex
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Sussex filed Critical University of Sussex
Priority to GBGB1702221.1A priority Critical patent/GB201702221D0/en
Publication of GB201702221D0 publication Critical patent/GB201702221D0/en
Priority to AU2018218307A priority patent/AU2018218307C1/en
Priority to NZ755747A priority patent/NZ755747A/en
Priority to PCT/GB2018/050370 priority patent/WO2018146486A1/en
Priority to CA3051647A priority patent/CA3051647C/en
Priority to EP18705480.4A priority patent/EP3580213B1/en
Priority to ES18705480T priority patent/ES2974824T3/es
Priority to RU2019126574A priority patent/RU2019126574A/ru
Priority to BR112019016603-3A priority patent/BR112019016603B1/pt
Priority to CN201880023973.3A priority patent/CN110520418B/zh
Priority to JP2019543832A priority patent/JP7014808B2/ja
Priority to MX2019009537A priority patent/MX2019009537A/es
Priority to KR1020197024520A priority patent/KR102665887B1/ko
Priority to US16/482,791 priority patent/US11186567B2/en
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
GBGB1702221.1A 2017-02-10 2017-02-10 Compounds Ceased GB201702221D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
GBGB1702221.1A GB201702221D0 (en) 2017-02-10 2017-02-10 Compounds
US16/482,791 US11186567B2 (en) 2017-02-10 2018-02-09 AMPA receptor potentiators
ES18705480T ES2974824T3 (es) 2017-02-10 2018-02-09 Potenciadores del receptor de AMPA
BR112019016603-3A BR112019016603B1 (pt) 2017-02-10 2018-02-09 Composto, uso deste e uma formulação farmacéutica
PCT/GB2018/050370 WO2018146486A1 (en) 2017-02-10 2018-02-09 Ampa receptor potentiators
CA3051647A CA3051647C (en) 2017-02-10 2018-02-09 Ampa receptor potentiators
EP18705480.4A EP3580213B1 (en) 2017-02-10 2018-02-09 Ampa receptor potentiators
AU2018218307A AU2018218307C1 (en) 2017-02-10 2018-02-09 AMPA receptor potentiators
RU2019126574A RU2019126574A (ru) 2017-02-10 2018-02-09 Потенциаторы рецепторов ampa
NZ755747A NZ755747A (en) 2017-02-10 2018-02-09 Ampa receptor potentiators
CN201880023973.3A CN110520418B (zh) 2017-02-10 2018-02-09 Ampa受体增强剂
JP2019543832A JP7014808B2 (ja) 2017-02-10 2018-02-09 Ampa受容体増強薬
MX2019009537A MX2019009537A (es) 2017-02-10 2018-02-09 Potenciadores del receptor de acido alfa-amino-3-hidroxi-5-metil-4 -isoxazol propionico (ampa).
KR1020197024520A KR102665887B1 (ko) 2017-02-10 2018-02-09 Ampa 수용체 강화제

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1702221.1A GB201702221D0 (en) 2017-02-10 2017-02-10 Compounds

Publications (1)

Publication Number Publication Date
GB201702221D0 true GB201702221D0 (en) 2017-03-29

Family

ID=58462168

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1702221.1A Ceased GB201702221D0 (en) 2017-02-10 2017-02-10 Compounds

Country Status (12)

Country Link
US (1) US11186567B2 (https=)
EP (1) EP3580213B1 (https=)
JP (1) JP7014808B2 (https=)
KR (1) KR102665887B1 (https=)
CN (1) CN110520418B (https=)
AU (1) AU2018218307C1 (https=)
ES (1) ES2974824T3 (https=)
GB (1) GB201702221D0 (https=)
MX (1) MX2019009537A (https=)
NZ (1) NZ755747A (https=)
RU (1) RU2019126574A (https=)
WO (1) WO2018146486A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds
CN121487750A (zh) * 2023-06-15 2026-02-06 上海魁特迪生物科技有限公司 Dir结合剂及其用途
CN121652294A (zh) * 2026-02-06 2026-03-13 首都医科大学宣武医院 一种用于检测抗ampar1抗体的融合蛋白及其用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW575561B (en) 1999-03-25 2004-02-11 Hoffmann La Roche 1-arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives
IL152848A0 (en) 2000-06-12 2003-06-24 Eisai Co Ltd 1,2-dihydropyridine derivatives, pharmaceutical compositions containing the same and methods for the production thereof
AU2003302027A1 (en) 2002-11-21 2004-06-15 Vicore Pharma Ab New tricyclic angiotensin ii agonists
JP5289043B2 (ja) 2005-04-12 2013-09-11 ヴィコール・ファルマ・アーベー 新規な三環系アンジオテンシンiiアゴニスト
CA2646585A1 (en) 2006-03-20 2007-09-27 Glaxo Group Limited Compounds which potentiate ampa receptor and uses thereof in medicine
EP2049475B1 (en) 2006-04-24 2012-02-01 Eli Lilly & Company Cyclohexyl substituted pyrrolidinones as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
TW200817385A (en) 2006-07-04 2008-04-16 Organon Nv Heterocyclic derivatives
DE602007013450D1 (de) * 2006-11-03 2011-05-05 Glaxo Group Ltd Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin
GB0711089D0 (en) * 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
GB0711088D0 (en) 2007-06-08 2007-07-18 Glaxo Group Ltd Compounds
EP2183228B1 (en) 2007-07-26 2014-08-20 Vitae Pharmaceuticals, Inc. CYCLIC INHIBITORS OF 11ß -HYDROXYSTERIOD DEHYDROGENASE 1
KR20100063087A (ko) 2007-09-20 2010-06-10 코텍스 파마슈티칼스, 인크. 글루타메이트 시냅스 반응 향상을 위한 3-치환된 1,2,3-트리아진-4-온 및 3-치환된 1,3-피리미디논
GB0721094D0 (en) 2007-10-26 2007-12-05 Glaxo Group Ltd Compounds
TW200934497A (en) 2007-11-13 2009-08-16 Organon Nv Heterocyclic derivatives
AR071236A1 (es) 2008-05-01 2010-06-02 Vitae Pharmaceuticals Inc Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1
TW201012803A (en) 2008-06-06 2010-04-01 Organon Nv Heterocyclic derivatives
TW201031649A (en) 2008-12-02 2010-09-01 Organon Nv 1-(4-(pyridin-2-yl)benzyl)imidazolidine-2,4-dione derivatives
AP3066A (en) 2009-06-26 2014-12-31 Pfizer Heterocyclic sulfonamides, uses and pharmaceuticalcompositions thereof
WO2011132051A2 (en) 2010-04-19 2011-10-27 Glenmark Pharmaceuticals S.A. Tricycle compounds as phosphodiesterase-10 inhibitors
UY33930A (es) 2011-03-04 2012-10-31 Novartis Ag Inhibidores novedosos de quinasas
GB201702221D0 (en) 2017-02-10 2017-03-29 Univ Of Sussex Compounds
GB201803340D0 (en) 2018-03-01 2018-04-18 Univ Of Sussex Compounds

Also Published As

Publication number Publication date
EP3580213A1 (en) 2019-12-18
RU2019126574A3 (https=) 2021-03-29
JP7014808B2 (ja) 2022-02-01
KR20190117549A (ko) 2019-10-16
MX2019009537A (es) 2019-10-04
AU2018218307C1 (en) 2022-06-23
KR102665887B1 (ko) 2024-05-10
RU2019126574A (ru) 2021-03-10
WO2018146486A1 (en) 2018-08-16
ES2974824T3 (es) 2024-07-01
CA3051647A1 (en) 2018-08-16
EP3580213C0 (en) 2024-03-27
AU2018218307A1 (en) 2019-08-15
EP3580213B1 (en) 2024-03-27
US11186567B2 (en) 2021-11-30
BR112019016603A2 (pt) 2020-03-31
CN110520418A (zh) 2019-11-29
NZ755747A (en) 2022-02-25
AU2018218307B2 (en) 2022-02-24
JP2020507592A (ja) 2020-03-12
CN110520418B (zh) 2022-08-16
US20210139463A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
GB201708456D0 (en) Senolytic compounds
GB201700814D0 (en) Compounds
GB201704327D0 (en) Compounds
GB201715342D0 (en) Compounds
GB201704325D0 (en) Compounds
GB201716871D0 (en) Compounds
GB201713962D0 (en) Compounds
GB201717051D0 (en) Compounds
GB201707938D0 (en) Compounds
GB201702221D0 (en) Compounds
GB201707856D0 (en) Compounds
GB201706162D0 (en) Compounds
GB201716369D0 (en) Compounds
GB201715786D0 (en) Compounds
GB201720064D0 (en) Compounds
GB201716392D0 (en) Compounds
GB201707852D0 (en) Compounds
GB201703282D0 (en) Compounds
GB201721326D0 (en) Compounds
GB201721330D0 (en) Compounds
GB201721331D0 (en) Compounds
GB201720495D0 (en) ß-lactone compounds
GB201719261D0 (en) Compounds
GB201717718D0 (en) Compounds
GB201717050D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)